A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications

A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications

The treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) by targeting Prostate Specific Membrane Antigen (PSMA), that is ubiquitously expressed on malicious cells, using177Lu-PSMA-617, has been showing great potential. Considering the promising results from Radioligand Therapy (RLT)...

Full description

Bibliographic Details
Main Authors:	K.S. Ajish Kumar, Anupam Mathur
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	European Journal of Medicinal Chemistry Reports
Subjects:	Nuclear Ligands PSMA Prostate Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772417422000565

Similar Items

Total chemical synthesis of PSMA-11: API for 68Ga-PSMA-11 used for prostate cancer diagnosis
by: K.S. Ajish Kumar, et al.
Published: (2021-12-01)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
by: Kristin A. Plichta, et al.
Published: (2021-11-01)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
by: Mark Topoozian, et al.
Published: (2023-09-01)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
by: Hui Wang, et al.
Published: (2023-11-01)

Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
by: Romain Schollhammer, et al.
Published: (2019-06-01)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
by: Catherine Meyer, et al.
Published: (2022-10-01)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
by: Kevin H. Leung, et al.
Published: (2022-12-01)

Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer
by: Melanie Hohberg, et al.
Published: (2019-07-01)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
by: Magdalena Staniszewska, et al.
Published: (2021-07-01)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
by: Alexander D. Combes, et al.
Published: (2022-10-01)

Exosomal Prostate-Specific Membrane Antigen (PSMA) and Caveolin-1 as Potential Biomarkers of Prostate Cancer—Evidence from Serbian Population
by: Suzana Matijašević Joković, et al.
Published: (2024-03-01)

Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer
by: Hu Siqi, Zhang Yong
Published: (2022-01-01)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
by: Claudia Arndt, et al.
Published: (2019-11-01)

The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer
by: Haidar Al Saffar, et al.
Published: (2024-02-01)

Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
by: Batool Albalooshi, et al.
Published: (2020-01-01)

PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties
by: Piotr Garnuszek, et al.
Published: (2021-03-01)

Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer
by: Cordula A. Jilg, et al.
Published: (2020-03-01)

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
by: José Carlos dos Santos, et al.
Published: (2022-08-01)

Differences in Distribution and Detection Rate of the [<sup>68</sup>Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11—Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer
by: Falk Gühne, et al.
Published: (2021-12-01)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with <sup>68</sup>Ga-PSMA PET/CT Features in Primary Staging
by: Luigia Vetrone, et al.
Published: (2023-03-01)

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
by: Ann-Christin Eder, et al.
Published: (2022-02-01)

Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review
by: Yuanzhuo Yan, et al.
Published: (2024-03-01)

Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance
by: Elham Ahmadi, et al.
Published: (2023-11-01)

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer
by: Niranjan Meher, et al.
Published: (2023-02-01)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024-02-01)

Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
by: Nicolai Mader, et al.
Published: (2023-09-01)

An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer
by: Ya’nan Ren, et al.
Published: (2022-04-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
by: Yaniv Yechiel, et al.
Published: (2023-02-01)

PSMA theragnostics for metastatic castration resistant prostate cancer
by: Hong Song, et al.
Published: (2022-08-01)

Lutetium-177-PSMA-617: A Vision of the Future
by: Elias Chandran, et al.
Published: (2022-12-01)

Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
by: Cristina Müller, et al.
Published: (2019-07-01)

Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy
by: Roswitha Runge, et al.
Published: (2023-04-01)

Histologically Confirmed Testicular Metastasis Revealed by [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging
by: Florian Rosar, et al.
Published: (2023-04-01)

Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer
by: Sazan Rasul, et al.
Published: (2022-08-01)

Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck
by: Thomas J. W. Klein Nulent, et al.
Published: (2020-06-01)

The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making—The Urological Perspective
by: Azik Hoffman, et al.
Published: (2023-06-01)

Plug inguinal hernia repair mimicking nodal spread of prostate cancer on PSMA-PET/CT
by: Genevieve C. Muñoz, MA, et al.
Published: (2023-01-01)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
by: Eugene Shenderov, et al.
Published: (2018-03-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)